Every 8-K that Omada Health, Inc. (OMDA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow OMDA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OMDA filings page.
Omada Health, Inc. delivered strong results for the quarter ended June 30, 2026, with revenue of $88 million, up 43% year over year, and GAAP gross margin of 73%, a quarterly record. Net income was $5 million versus a $5 million loss in Q2 2025, and adjusted EBITDA reached a record $11 million. Total Members increased 45% year over year, trailing twelve‑month revenue per member was $284, and cash and cash equivalents totaled $222 million.
Full‑year 2026 guidance was raised to $334–$340 million of revenue and $21–$27 million of adjusted EBITDA, with midpoints implying 30% revenue growth and a fourfold increase in adjusted EBITDA versus 2025. Effective January 1, 2027, co‑founder Sean Duffy will become Founder and Executive Chair, President Wei‑Li Shao will assume the role of Chief Executive Officer and join the Board as a Class I director, and Jeryl Hilleman will become Lead Independent Director.
Omada Health, Inc. held its 2026 annual stockholder meeting on June 16, 2026. Common stockholders of record as of April 20, 2026 were entitled to one vote per share.
Stockholders elected Sean Duffy and Trevor Fetter as Class I directors to serve until the 2029 annual meeting. Duffy received 18,540,089 votes for and 9,134,162 withheld, while Fetter received 18,538,042 votes for and 9,136,209 withheld, with 13,920,625 broker non-votes for each nominee.
Stockholders also ratified the appointment of Deloitte & Touche LLP as Omada Health’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with 41,550,689 votes for, 16,905 against, and 27,282 abstentions.
Omada Health reported strong first-quarter 2026 growth with improving profitability metrics. Revenue reached $78.0 million for the three months ended March 31, 2026, up 42% year over year, while Total Members grew to 1.02 million, a 51% increase, highlighting expanding adoption of its virtual cardiometabolic care platform.
GAAP gross margin improved to 62%, and non-GAAP gross margin to 64%. Net loss narrowed to $3.0 million from $9.4 million a year earlier, and adjusted EBITDA turned positive at $0.9 million versus a $4.2 million loss. Omada ended the quarter with $211.8 million of cash and cash equivalents and raised its full-year 2026 revenue and adjusted EBITDA outlook.
Omada Health, Inc. reported rapid growth and a key profitability milestone for 2025. Total members reached 886,000 at year end, up 55% year over year, reflecting strong demand for its virtual chronic care programs.
Revenue was $76 million in the fourth quarter, up 58% year over year, and $260 million for the full year, up 53% compared with 2024. Gross margin improved to 71% in the fourth quarter and 66% for the year, indicating better unit economics. The company generated net income of $5 million in the fourth quarter versus a net loss a year earlier, and narrowed its full‑year net loss to $13 million from $47 million. Adjusted EBITDA turned positive at $8 million in the fourth quarter and $6 million for the year.
Cash and cash equivalents were $222 million as of December 31, 2025, supported by IPO proceeds and debt repayment, leaving no long‑term debt. For 2026, Omada expects revenue between $312 million and $322 million and adjusted EBITDA between $7 million and $15 million, implying continued growth with maintained profitability on an adjusted basis.
Omada Health, Inc. furnished an update on its recent performance by announcing preliminary, unaudited revenue for the fourth quarter and full fiscal year ended December 31, 2025. The company disclosed this information in connection with a public webcast presentation at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. The preliminary figures are subject to completion of Omada’s year-end closing procedures and its annual independent audit and may be adjusted. The revenue details are contained in a press release attached as Exhibit 99.1, which is furnished rather than filed, meaning it is not subject to certain Exchange Act liabilities or automatically incorporated into other SEC reports.
Omada Health, Inc. (OMDA) reported that it issued a press release announcing financial results for the three months ended September 30, 2025. The press release is furnished as Exhibit 99.1 to a Form 8-K under Item 2.02 and, as stated, is furnished and not deemed filed under Section 18 of the Exchange Act, nor incorporated by reference except as specifically referenced.